Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar:147:112671.
doi: 10.1016/j.biopha.2022.112671. Epub 2022 Jan 29.

Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update

Allison D Desforges  1 , Chance M Hebert  2 , Allyson L Spence  3 , Bailey Reid  4 , Hemangini A Dhaibar  5 , Diana Cruz-Topete  6 , Elyse M Cornett  7 , Alan David Kaye  8 , Ivan Urits  9 , Omar Viswanath  10
Affiliations
Review

Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update

Allison D Desforges et al. Biomed Pharmacother. 2022 Mar.

Abstract

When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory rather than motor and include reduced feeling and heightened sensitivity to pressure, pain, temperature, and touch. The pathophysiology of CIPN is very complex, and it involves multiple mechanisms leading to its development which will be described specifically for each chemotherapeutic class. There are currently no approved or effective agents for CIPN prevention, and Duloxetine is the only medication that is an effective treatment against CIPN. There is an unavoidable necessity to develop preventative and treatment approaches for CIPN due to its detrimental impact on patients' lives. The purpose of this review is to examine CIPN, innovative pharmacological and nonpharmacological therapy and preventive strategies for this illness, and future perspectives for this condition and its therapies.

Keywords: Chemotherapy-induced peripheral neuropathy; Ion channel-targeted therapies; Neuropathy; Pain; Pain management.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

None

References

    1. Barrell K, Smith AG, Peripheral neuropathy, Med. Clin. North Am 103 (2) (2019) 383–397. - PubMed
    1. Brown TJ, Sedhom R, Gupta A, Chemotherapy-induced peripheral neuropathy, JAMA Oncol. 5 (5) (2019) 750. - PubMed
    1. Miltenburg NC, Boogerd W, Chemotherapy-induced neuropathy: a comprehensive survey, Cancer Treat. Rev 40 (7) (2014) 872–882. - PubMed
    1. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, Von Roenn JH, NCCN task force report: management of neuropathy in cancer, JNCCN J. Natl. Compr. Cancer Netw 7 (SUPPL. 5) (2009) 1–26. - PubMed
    1. Cavaletti G, Marmiroli P, Chemotherapy-induced peripheral neurotoxicity, Nat. Rev. Neurol 6 (12) (2010) 657–666. - PubMed

MeSH terms

Substances